You are currently browsing the archives for 24 August 2017.
Displaying 1 - 2 of 2 entries.

Axentis Pharma AG today announced that.

Gergely Lukacs who guided the experimental set-up in his labs at the Ill Kids Medical center in Toronto clarifies: In sufferers with cystic fibrosis, the proteins CFTR with mutated framework can be marked with ubiquitin. These ubiquitin-marked proteins are prematurely degraded by multiple mechanisms. If this marker is certainly missing, the proteins evades destruction and may regulate the focus of drinking water and salt secretion in the lung despite its minimal structural defect.

BIOGUARD barrier gauze dressings give high antiviral efficacy against H1N1 Derma Sciences.

BIOGUARD barrier gauze dressings give high antiviral efficacy against H1N1 Derma Sciences, Inc. , a specialty medical gadget and pharmaceutical company centered on advanced wound treatment, today released an unbiased laboratory record indicating that the business’s BIOGUARD barrier gauze dressings exhibit high antiviral efficacy against the H1N1 virus. This new details escalates the applicability of the dressings, that have already been proven to possess high efficacy against virulent bacterias such as for example MRSA. BCS Laboratories Inc. Of Gainesville, Florida uncovered two types of BIOGUARD dressings to levels of the Influenza A virus for an interval of 24 hours.